Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
10 July 2015 |
Main ID: |
EUCTR2012-005778-74-NL |
Date of registration:
|
06/03/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes
|
Scientific title:
|
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes. A 26 week randomised, insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-centre trial - ADJUNCT TWO™ |
Date of first enrolment:
|
09/05/2014 |
Target sample size:
|
804 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005778-74 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 6
|
Phase:
|
|
|
Countries of recruitment
|
Austria
|
Belgium
|
Bulgaria
|
Canada
|
Denmark
|
European Union
|
Finland
|
Netherlands
|
South Africa
|
Spain
|
Sweden
|
United States
| | | | |
Contacts
|
Name:
|
Global Clinical Registry (GCR,1452)
|
Address:
|
Vandtårnsvej 114, VTB
2860
Søborg
Denmark |
Telephone:
|
|
Email:
|
clinicaltrials@novonordisk.com |
Affiliation:
|
Novo Nordisk A/S |
|
Name:
|
Global Clinical Registry (GCR,1452)
|
Address:
|
Vandtårnsvej 114, VTB
2860
Søborg
Denmark |
Telephone:
|
|
Email:
|
clinicaltrials@novonordisk.com |
Affiliation:
|
Novo Nordisk A/S |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
2. Male or female, aged = 18 years at the time of signing informed consent
3. Type 1 diabetes mellitus (as diagnosed clinically) = 12 months prior to Visit 1 (i.e. screening)
4. Treatment with basal bolus or CSII (continuous subcutaneous insulin infusion, insulin pump) treatment = 6 months prior to Visit 1 (i.e. screening)
5. Stable insulin treatment = 3 months prior to Visit 1 (i.e. screening), as judged and documented by the investigator
6. HbA1c 7.0–10.0 % (Diabetes Control and Complications Trial (DCCT)), both inclusive, by central laboratory analysis (Visit 1, screening) corresponding to 53–86 mmol/mol (International Federation of Clinical Chemistry (IFCC)) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 744 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60
Exclusion criteria: 1. Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPPIV) inhibitors
2. Use of any medication, which in the investigator’s opinion could interfere with the glycaemic control (e.g. systemic corticosteroids, pramlintide (Symlin®)) or affect the subject’s safety. Premix insulin is not allowed
3. Known proliferative retinopathy or maculopathy requiring acute treatment
4. Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator
5. Uncontrolled/ untreated blood pressure at screening (Visit 1) (after resting for 5 min) while sitting > 160 mmHg for systolic or >100 mmHg for diastolic (repeated measurement at Visit 2 (prior to performing the trial related activities) is allowed to exclude white-coat hypertension)
6. History of acute or chronic pancreatitis
7. Screening (Visit 1) calcitonin value = 50 ng/L
8. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
9. Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Diabetes Mellitus, Type 1 MedDRA version: 16.1
Level: LLT
Classification code 10045228
Term: Type I diabetes mellitus
System Organ Class: 100000004861
|
Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
|
Intervention(s)
|
Trade Name: Victoza Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: LIRAGLUTIDE CAS Number: 204656-20-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6.0- Pharmaceutical form of the placebo: Solution for injection in pre-filled pen Route of administration of the placebo: Subcutaneous use
|
Primary Outcome(s)
|
Secondary Objective: 1. To confirm superiority of liraglutide compared to placebo, both adjunct to insulin treatment, with regards to body weight loss after 26 weeks of treatment in subjects with established type 1 diabetes in inadequate glycaemic control. 2. To evaluate safety and tolerability of liraglutide compared to placebo, both adjunct to insulin treatment, during 26 weeks of treatment in subjects with type 1 diabetes in inadequate glycaemic control.
|
Main Objective: To confirm superiority of liraglutide compared to placebo, both adjunct to insulin treatment, on glycaemic control, after 26 weeks of treatment in subjects with established type 1 diabetes in inadequate glycaemic control.
|
Primary end point(s): Change from baseline in glycosylated haemoglobin (HbA1c)
|
Timepoint(s) of evaluation of this end point: After 26 weeks of treatment
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: 1. After 26 weeks of treatment
2. During 26 weeks of treatment
|
Secondary end point(s): 1. Change from baseline in body weight
2. Number of treatment-emergent symptomatic hypoglycaemic episodes
|
Secondary ID(s)
|
2012-005778-74-AT
|
NN9211-4083
|
Source(s) of Monetary Support
|
Novo Nordisk A/S
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|